In the coming year it will be interesting to note how these trends impact the growing debate around lab-developed test regulation. The US Food and Drug Administration proposal to regulate LDTs � many of which utilize PCR or other nucleic acid amplification technologies � will likely continue to be a�contentious�topic, and could ultimately change established pathways of diagnostics development and commercialization.